Sleep Medicine for Adults: Evaluation and Management
Initial Treatment Approach
All adults with chronic insomnia disorder should receive cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment before considering any medications. 1
This is a strong recommendation from the American College of Physicians based on moderate-quality evidence showing CBT-I improves:
- Sleep onset latency and wake after sleep onset
- Sleep efficiency and quality
- Global outcomes including remission rates and symptom severity scores
- Benefits persist in both general adult and older adult populations
CBT-I Components and Delivery
CBT-I consists of three integrated elements:
- Cognitive therapy addressing dysfunctional beliefs about sleep
- Behavioral interventions including sleep restriction and stimulus control
- Sleep hygiene education
Delivery methods (all shown to be effective):
- In-person individual or group therapy
- Telephone-based modules
- Web-based programs
- Self-help books
CBT-I can be performed in primary care settings and harms are likely mild given the noninvasive nature 1.
When CBT-I Alone Fails
If CBT-I is unsuccessful, use shared decision-making to discuss adding short-term pharmacotherapy, explicitly covering benefits, harms, and costs. 1
This is a weak recommendation based on low-quality evidence, reflecting:
- Insufficient data on comparative safety between medications
- Serious adverse effects from observational studies linking hypnotics to dementia and fractures 1
- FDA warnings about cognitive/behavioral changes, driving impairment, and motor vehicle accidents
Critical Medication Caveats
FDA-recommended precautions:
- Lower doses required for women, older adults, and debilitated patients
- Short-term use recommended (≤4 weeks for most agents)
- Many patients continue use for extended periods despite recommendations 1
Available pharmacologic options include:
- Benzodiazepines (triazolam, estazolam, temazepam, flurazepam, quazepam)
- Nonbenzodiazepine hypnotics (zaleplon, zolpidem, eszopiclone)
- Orexin receptor antagonists (suvorexant, daridorexant - can be used up to 3 months) 2
- Melatonin receptor agonists (ramelteon)
- Low-dose sedating antidepressants (doxepin)
- Prolonged-release melatonin (for patients ≥55 years, up to 3 months) 2
Avoid: Antihistamines, antipsychotics, fast-release melatonin, and phytotherapeutics are not recommended 2.
Combination Therapy Considerations
The American Academy of Sleep Medicine suggests against routinely combining CBT-I with medication over CBT-I alone (conditional recommendation, low certainty) 3. However, combination treatment may be reasonable for patients who:
- Prioritize rapid improvement in total sleep time early in treatment
- Place lower value on reducing daytime symptoms
When combination therapy is used, it should involve CBT-I started concurrently with pharmacotherapy 3.
Diagnostic Criteria for Chronic Insomnia
Diagnosis requires all of the following per DSM-5 criteria 1:
- Dissatisfaction with sleep quantity or quality
- Difficulty initiating sleep, maintaining sleep, OR early-morning awakening with inability to return to sleep
- Present ≥3 nights per week for ≥3 months
- Causes clinically significant functional distress or impairment
- Not attributable to other sleep, medical, or mental disorders
Age-specific patterns: Older adults more commonly report difficulty maintaining sleep (wake after sleep onset) rather than sleep onset latency 1.
Evaluation Components
Required assessment elements:
- Clinical interview covering sleep and medical history
- Sleep questionnaires and sleep diaries
- Physical examination when indicated 2
Actigraphy: Not recommended for routine insomnia evaluation but may be useful for differential diagnosis 2.
Polysomnography indications:
- Suspected comorbid sleep disorders (periodic limb movement disorder, sleep-disordered breathing)
- Treatment-resistant insomnia
- Differential diagnostic purposes 2
Obstructive Sleep Apnea Management
For patients with excessive daytime sleepiness and diagnosed OSA:
Continuous positive airway pressure (CPAP) is the initial treatment (strong recommendation, moderate-quality evidence) 4. CPAP improves:
- Excessive sleepiness scores
- Apnea-hypopnea index
- Oxygen saturation
Mandibular advancement devices (MADs) are an alternative for patients who:
- Prefer MADs over CPAP
- Experience adverse effects with CPAP
- Cannot tolerate or adhere to CPAP 4
Pharmacologic agents are not supported by evidence for OSA treatment and should not be prescribed 4.